查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951164

化學冷光免疫檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、樣品類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Chemiluminescence Immunoassay Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product, By Sample Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球化學冷光免疫檢測(CLIA) 市場預計將從 2025 年的 126.3 億美元成長到 2031 年的 169.4 億美元，複合年成長率為 5.02%。

化學冷光免疫檢測(CLIA) 是一種重要的診斷技術，它利用化學反應產生光，從而能夠對臨床檢體中的抗原和抗體進行精確定量。此市場成長的主要驅動力是全球慢性病和感染疾病病率的上升，這反過來又增加了檢查室對精確、高通量檢測的需求。 MedTech Europe 2024 的估計值顯示歐洲醫療技術市場價值約為 1,700 億歐元，其中體外診斷佔最大佔有率。

市場概覽
預測期 2027-2031
市場規模：2025年 126.3億美元
市場規模：2031年 169.4億美元
複合年成長率：2026-2031年 5.02%
成長最快的細分市場 消耗品
最大的市場 北美洲

然而，自動化分析儀平台所需的大量資本投入阻礙了市場擴張。這些儀器的高昂購買成本，加上試劑的持續成本以及對專業人員的需求，對資源匱乏地區的小規模醫療機構和檢查室構成了巨大的經濟障礙。因此，這些經濟限制因素可能成為阻礙這項先進診斷技術廣泛應用的主要因素。

市場促進因素

全球慢性病和感染疾病負擔日益加重，是推動全球化學冷光免疫檢測市場發展的主要動力。與傳統方法相比，CLIA 具有更高的靈敏度和更寬的檢測範圍，因此臨床檢查室越來越依賴 CLIA。在腫瘤學領域，準確的生物標記檢測對於早期診斷至關重要。根據美國癌症協會發布的《2025 年癌症事實與數據》，預計到 2025 年，美國將新增 2,041,910 例癌症病例，將對免疫檢測檢測產生巨大的需求。同樣，高靈敏度的診斷工具在感染疾病管理中也至關重要，因為早期發現是改善患者預後的關鍵，這進一步鞏固了該技術在醫療保健領域的作用。

同時，自動化、高通量化學發光免疫分析（CLIA）平台的技術進步正在解決現代實驗室的營運難題，加速市場成長。診斷中心正從手動ELISA方法轉向全自動系統，以滿足不斷成長的檢測量，同時縮短處理時間並減少誤差。這一趨勢在行業財務數據中也得到了體現。羅氏2024年年度報告預測，在免疫診斷需求的推動下，其診斷業務銷售額將達到143億瑞士法郎。此外，雅培於2025年1月發布的「2024年第四季及全年業績」報告預測，不計新冠肺炎疫情，其全球診斷業務銷售額將成長4.3%，凸顯了核心診斷技術的持續應用。

市場挑戰

自動化化學冷光免疫檢測(CLIA) 分析儀需要大量的資金投入，這嚴重限制了市場成長。資源匱乏地區的小規模實驗室和醫療機構往往缺乏資金來承擔此類精密設備的高昂初始投資成本。此外，持續的營運成本，例如專用試劑和維護費用，也進一步加重了本就捉襟見肘的預算。因此，許多機構仍然依賴低成本的檢測方法，例如酶聯免疫吸附試驗 (ELISA)，這限制了 CLIA 技術的廣泛應用，並直接阻礙了市場擴張。

這些資金限制也清楚地反映在產業的支出模式中，揭示了診斷領域資源的匱乏。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，體外診斷支出將約佔醫療保健總支出的0.6%。這項數據表明，與醫療保健總支出相比，診斷領域的資金分配明顯偏低。資金分配的不足限制了檢查室的購買力，使得購買昂貴的自動化CLIA平台對很大一部分潛在基本客群在經濟上難以負擔。

市場趨勢

新型生物標記在早期檢測領域的應用日益廣泛，從根本上重塑了市場格局，促使臨床檢查室從常規檢測轉向高附加價值的專業檢測。這一趨勢包括快速採用先進的化學冷光檢測法來診斷自體免疫疾病、內分泌失調和潛伏性行為感染等複雜病症，這些技術相比傳統方法具有更高的特異性。製造商正積極將這些小眾生物標記添加到其檢測項目中，以確保更高的報銷率和臨床意義。這項策略也體現在財務表現上。 DiaSorin公司於2025年3月發布的2024會計年度財務報告顯示，其免疫診斷藥物銷售額（不包括與COVID-19相關的項目）同比成長9%，並指出其專業檢測項目的擴展是關鍵因素。

同時，市場正透過併購進行策略重組，旨在提高營運效率並整合產品系列。為了解決醫療服務分散的問題，領先的診斷公司正在建立診斷生態系統，將照護現場能力與核心檢查室基礎設施結合。這些併購使公司能夠實現顯著的成本協同效應，並透過簡化生產流程來抵消高額的資本支出。 QuidelOrtho 於 2025 年 8 月發布的「2025 會計年度第二季財務業績」凸顯了這項以效率為導向的舉措所取得的成功，該業績報告顯示，公司實現了 1 億美元的年度成本節約，驗證了近期整合舉措的有效性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球化學冷光免疫檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（設備{自動化、半自動化}、耗材、軟體和服務）
    • 依樣本類型（血液、尿液、唾液、其他）
    • 依應用領域（治療藥物監測、腫瘤學、心臟病學、內分泌學、感染疾病、自體免疫疾病、其他）
    • 按最終用戶（醫院、臨床檢查室、製藥和生物技術公司、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美化學冷光免疫檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲化學冷光免疫檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區化學冷光免疫檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲化學冷光免疫檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲化學冷光免疫檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球化學冷光免疫檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Beckman Coulter, Inc
  • DiaSorin SpA
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • QuidelOrtho Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24283

The Global Chemiluminescence Immunoassay Market is projected to expand from USD 12.63 Billion in 2025 to USD 16.94 Billion by 2031, achieving a compound annual growth rate of 5.02%. Chemiluminescence Immunoassay (CLIA) serves as a vital diagnostic technique that utilizes chemical reactions to emit light, allowing for the precise quantification of antigens and antibodies in clinical samples. This market growth is fundamentally propelled by the rising global prevalence of chronic and infectious diseases, which drives the need for accurate, high-throughput testing in laboratories. The scale of this demand is highlighted by the MedTech Europe 2024 estimate, which valued the European medical technology market at approximately €170 billion, with in vitro diagnostics representing the largest segment.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 12.63 Billion
Market Size 2031USD 16.94 Billion
CAGR 2026-20315.02%
Fastest Growing SegmentConsumables
Largest MarketNorth America

However, the market's expansion faces significant hurdles due to the substantial capital investment necessary for automated analyzer platforms. The high acquisition costs of these instruments, along with ongoing expenses for reagents and the need for specialized personnel, create a formidable financial barrier for smaller healthcare facilities and laboratories in resource-limited areas. Consequently, these economic constraints act as a primary impediment, potentially slowing the widespread adoption of this advanced diagnostic technology.

Market Driver

The increasing global burden of chronic and infectious diseases serves as a primary catalyst for the Global Chemiluminescence Immunoassay Market. Clinical laboratories increasingly rely on CLIA due to its superior sensitivity and broad dynamic range compared to traditional methods. In oncology, precise biomarker detection is essential for early diagnosis; the American Cancer Society's "Cancer Facts & Figures 2025" projects 2,041,910 new cancer cases in the United States in 2025, generating immense demand for immunoassay testing. Similarly, high-sensitivity diagnostic tools are crucial for managing infectious diseases, where early detection is key to improving patient outcomes, further solidifying the technology's role in healthcare.

Simultaneously, technological progress in automated, high-throughput CLIA platforms is accelerating market growth by addressing operational challenges in modern laboratories. Diagnostic centers are shifting from manual ELISA methods to fully automated systems to handle rising testing volumes with faster turnaround times and reduced errors. This trend is evident in industry financials; the Roche Annual Report 2024 noted Diagnostics Division sales of CHF 14.3 billion, driven by immunodiagnostic demand. Furthermore, Abbott's "Fourth Quarter and Full-Year 2024 Results" from January 2025 showed a 4.3 percent rise in global Diagnostics sales excluding COVID-19, highlighting the sustained uptake of core diagnostic technologies.

Market Challenge

The significant capital required for automated chemiluminescence immunoassay (CLIA) analyzers acts as a major restraint on market growth. Smaller laboratories and healthcare facilities in resource-limited settings often lack the funds to cover the high upfront acquisition costs of these sophisticated instruments. Furthermore, recurring operational expenses, such as proprietary reagents and specialized maintenance, place additional strain on limited budgets. Consequently, many institutions remain reliant on lower-cost methods like ELISA, which restricts the broader adoption of CLIA technology and directly hinders market expansion.

These financial constraints are clearly reflected in industry spending patterns, which reveal limited resources for diagnostic departments. According to MedTech Europe, expenditure on in vitro diagnostics accounted for approximately 0.6% of total healthcare spending in 2024. This statistic underscores the disproportionately low funding allocated to the diagnostics sector relative to overall healthcare expenditure. Such restricted financial allocation limits the purchasing power of laboratories, rendering the procurement of expensive automated CLIA platforms financially unviable for a significant portion of the potential customer base.

Market Trends

The increased application of novel biomarkers for early detection is fundamentally reshaping the market, prompting clinical laboratories to shift from routine screening to high-value specialty testing. This trend involves the rapid adoption of advanced chemiluminescence assays for complex conditions like autoimmunity, endocrinology, and latent infectious diseases, which offer superior specificity compared to traditional methods. Manufacturers are aggressively broadening their test menus to include these niche biomarkers, thereby securing higher reimbursement rates and clinical relevance. This strategy is reflected financially; DiaSorin's "FY 2024 Results" in March 2025 reported a 9% year-over-year increase in ex-COVID immunodiagnostic revenues, explicitly attributed to the expansion of its specialty test menu.

Simultaneously, the market is undergoing strategic consolidation through mergers and acquisitions aimed at enhancing operational efficiency and portfolio integration. Major diagnostic players are combining point-of-care capabilities with core laboratory infrastructure to build unified diagnostic ecosystems that address fragmented healthcare delivery. These mergers enable companies to realize significant cost synergies and streamline manufacturing to offset high capital equipment costs. The success of this focus on efficiency is visible in QuidelOrtho's "Second Quarter 2025 Results" from August 2025, which announced the realization of $100 million in annualized cost savings, validating the benefits of recent integration initiatives.

Key Market Players

  • Abbott Laboratories Inc.
  • Beckman Coulter, Inc
  • DiaSorin S.p.A
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • QuidelOrtho Corporation

Report Scope

In this report, the Global Chemiluminescence Immunoassay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemiluminescence Immunoassay Market, By Product

  • Instruments {Automated, Semi-automated}
  • Consumables
  • Software & Services

Chemiluminescence Immunoassay Market, By Sample Type

  • Blood
  • Urine
  • Saliva
  • Other

Chemiluminescence Immunoassay Market, By Application

  • Therapeutic Drug Monitoring
  • Oncology
  • Cardiology
  • Endocrinology
  • Infectious Disease
  • Autoimmune Disease
  • Other

Chemiluminescence Immunoassay Market, By End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Other

Chemiluminescence Immunoassay Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemiluminescence Immunoassay Market.

Available Customizations:

Global Chemiluminescence Immunoassay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemiluminescence Immunoassay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments {Automated, Semi-automated}, Consumables, Software & Services)
    • 5.2.2. By Sample Type (Blood, Urine, Saliva, Other)
    • 5.2.3. By Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, Other)
    • 5.2.4. By End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Other)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Chemiluminescence Immunoassay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Sample Type
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chemiluminescence Immunoassay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Sample Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Chemiluminescence Immunoassay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Sample Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Chemiluminescence Immunoassay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Sample Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Chemiluminescence Immunoassay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Sample Type
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chemiluminescence Immunoassay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Sample Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France Chemiluminescence Immunoassay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Sample Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Chemiluminescence Immunoassay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Sample Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Chemiluminescence Immunoassay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Sample Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Chemiluminescence Immunoassay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Sample Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific Chemiluminescence Immunoassay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Sample Type
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chemiluminescence Immunoassay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Sample Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Chemiluminescence Immunoassay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Sample Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Chemiluminescence Immunoassay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Sample Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Chemiluminescence Immunoassay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Sample Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Chemiluminescence Immunoassay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Sample Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa Chemiluminescence Immunoassay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Sample Type
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chemiluminescence Immunoassay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Sample Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Chemiluminescence Immunoassay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Sample Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Chemiluminescence Immunoassay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Sample Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America Chemiluminescence Immunoassay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Sample Type
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chemiluminescence Immunoassay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Sample Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Chemiluminescence Immunoassay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Sample Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Chemiluminescence Immunoassay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Sample Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chemiluminescence Immunoassay Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Beckman Coulter, Inc
  • 15.3. DiaSorin S.p.A
  • 15.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 15.5. F. Hoffmann-La Roche Ltd
  • 15.6. Siemens Healthineers AG
  • 15.7. QuidelOrtho Corporation

16. Strategic Recommendations

17. About Us & Disclaimer